Biogen and Alkermes have entered into a global license and collaboration agreement to develop and commercialize ALKS 8700, a novel, oral, monomethyl fumarate small drug molecule in Phase 3 development for the treatment of relapsing forms of multiple sclerosis.   Biogen will receive an exclusive, worldwide license to commercialize ALKS 8700 and will pay Alkermes a mid-teens royalty on worldwide net sales of the drug. Biogen will also reimburse Alkermes for fifty percent of the 2017 develo...